Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
5 citing papers in PubMed, 11 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 3 institutions in 4 countries.
Mustafa M AldferSchool of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK.ORCID 0000-0003-3998-7642
Ibrahim A AlfayezSchool of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK.ORCID 0000-0003-3769-4715
Hamza A A ElatiSchool of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK.ORCID 0000-0002-9339-6002
Nilanjana GayenSchool of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK.
Ehab Kotb ElmahallawySchool of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK.ORCID 0000-0003-4484-3678
Ana Milena MurilloDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil.
Sabrina MarsiccobetreDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil.ORCID 0000-0002-9622-4767
Serge Van CalenberghLaboratory for Medicinal Chemistry (Campus Heymans), Ghent University, B-9000 Gent, Belgium.ORCID 0000-0002-4201-1264
Ariel M SilberDepartment of Parasitology, Institute of Biomedical Sciences, University of São Paulo, São Paulo 05508-000, Brazil.
Harry P de KoningSchool of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G12 8TA, UK.ORCID 0000-0002-9963-1827
University of Glasgow · GBUniversidade de São Paulo · BRGhent University · BE
Funding
Academy of Medical Sciences Daniel Turnberg FellowshipCovernment of Libya Studentships to M.A.A. and H.A..A.E.Medical Research Council MR/P027989/1Royal Society Newton Research Travel GrantSaudi Arabia Ministry of Health studentship to I.A.A.
6 · The paper itself
Abstract
Among the scarce validated drug targets against Chagas disease (CD), caused by
Indexed as
Chagas DiseaseTrypanosoma cruziBiological TransportDeoxyuridineHumansNucleoside Transport ProteinsTubercidinDeoxyuridineNucleoside Transport ProteinsTubercidin5-F-2′-deoxyuridineantimetabolitenucleoside transporterpyrimidine transporterTcrNT2thymidineTrypanosoma cruzitubercidin analog
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.